Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 2
2006 1
2007 2
2008 3
2009 3
2010 1
2011 2
2012 2
2013 8
2014 7
2015 7
2016 6
2017 9
2018 7
2019 10
2020 10
2021 10
2022 12
2023 19
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J; NefIgArd trial investigators. Lafayette R, et al. Lancet. 2023 Sep 9;402(10405):859-870. doi: 10.1016/S0140-6736(23)01554-4. Epub 2023 Aug 14. Lancet. 2023. PMID: 37591292 Clinical Trial.
Renal physiology of pregnancy.
Cheung KL, Lafayette RA. Cheung KL, et al. Among authors: lafayette ra. Adv Chronic Kidney Dis. 2013 May;20(3):209-14. doi: 10.1053/j.ackd.2013.01.012. Adv Chronic Kidney Dis. 2013. PMID: 23928384 Free PMC article. Review.
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Jüni P, Cattran DC; MENTOR Investigators. Fervenza FC, et al. Among authors: lafayette ra. N Engl J Med. 2019 Jul 4;381(1):36-46. doi: 10.1056/NEJMoa1814427. N Engl J Med. 2019. PMID: 31269364 Clinical Trial.
IgA nephropathy: the lectin pathway and implications for targeted therapy.
Barratt J, Lafayette RA, Zhang H, Tesar V, Rovin BH, Tumlin JA, Reich HN, Floege J. Barratt J, et al. Among authors: lafayette ra. Kidney Int. 2023 Aug;104(2):254-264. doi: 10.1016/j.kint.2023.04.029. Epub 2023 May 30. Kidney Int. 2023. PMID: 37263354 Free article. Review.
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Barratt J, et al. Among authors: lafayette r. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Free article. Clinical Trial.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Among authors: lafayette r. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
The Significance of Hematuria in Podocytopathies.
Marchel D, Trachtman H, Larkina M, Helmuth M, Lai Yee JY, Fermin D, Bomback AS, Canetta PA, Gipson DS, Mottl AK, Parekh RS, Saha MK, Sampson MG, Lafayette RA, Mariani LH; Nephrotic Syndrome Study Network (NEPTUNE) and Cure Glomerulonephropathy (CureGN). Marchel D, et al. Among authors: lafayette ra. Clin J Am Soc Nephrol. 2024 Jan 1;19(1):56-66. doi: 10.2215/CJN.0000000000000309. Epub 2023 Sep 21. Clin J Am Soc Nephrol. 2024. PMID: 37733352
Considering the Treatment of IgA Nephropathy.
Lafayette RA, Kamal FS. Lafayette RA, et al. Clin J Am Soc Nephrol. 2023 Sep 1;18(9):1113-1115. doi: 10.2215/CJN.0000000000000261. Epub 2023 Aug 3. Clin J Am Soc Nephrol. 2023. PMID: 37533148 Free PMC article. No abstract available.
Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy.
Barbour SJ, Fervenza FC, Induruwage D, Brenchley PE, Rovin B, Hladunewich MA, Reich HN, Lafayette R, Aslam N, Appel GB, Zand L, Kiryluk K, Liu L, Cattran DC; MENTOR Trial Investigators. Barbour SJ, et al. Among authors: lafayette r. Clin J Am Soc Nephrol. 2023 Oct 1;18(10):1283-1293. doi: 10.2215/CJN.0000000000000237. Epub 2023 Jul 20. Clin J Am Soc Nephrol. 2023. PMID: 37471101
106 results